Loteprednol/tobramycin

{{Short description|Medication}}

{{Use American English|date=December 2023}}

{{Use dmy dates|date=December 2023}}

{{cs1 config |name-list-style=vanc |display-authors=6}}

{{Infobox drug

| drug_name =

| type = combo

| image =

| width =

| alt =

| caption =

| component1 = Loteprednol

| class1 = Corticosteroid

| component2 = Tobramycin

| class2 = Aminoglycoside antibiotic

| tradename = Zylet

| Drugs.com = {{drugs.com|cons|loteprednol-and-tobramycin}}

| MedlinePlus =

| DailyMedID = Loteprednol and tobramycin

| pregnancy_AU =

| pregnancy_AU_comment =

| pregnancy_category =

| routes_of_administration = Ophthalmic

| ATCvet =

| ATC_prefix = S01

| ATC_suffix = CA12

| ATC_supplemental =

| legal_AU =

| legal_AU_comment =

| legal_BR =

| legal_BR_comment =

| legal_CA =

| legal_CA_comment =

| legal_DE =

| legal_DE_comment =

| legal_NZ =

| legal_NZ_comment =

| legal_UK =

| legal_UK_comment =

| legal_US = Rx-only

| legal_US_comment = {{cite web | title=Zylet- loteprednol etabonate and tobramycin suspension/ drops | website=DailyMed | date=30 April 2022 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3dd9b060-5355-404d-bdf1-09ee8b52a9f5 | access-date=25 December 2023}}

| legal_EU =

| legal_EU_comment =

| legal_UN =

| legal_UN_comment =

| legal_status =

| CAS_number = 863983-05-5

| CAS_supplemental =

| PubChem =

| PubChemSubstance =

| IUPHAR_ligand =

| DrugBank =

| ChemSpiderID =

| UNII =

| KEGG = D12133

| ChEBI =

| ChEMBL =

| synonyms =

}}

Loteprednol/tobramycin, sold under the brand name Zylet, is a fixed-dose combination medication used for the treatment of inflammation of the eye. It is a combination of loteprednol, as the etabonate, a corticosteroid; and tobramycin, an aminoglycoside antibiotic. It is used as drops in the eye.

Loteprednol/tobramycin was approved for medical use in the United States in December 2004.